1.Systematic understanding of acute effects of intravenous guanfacine on rat carotid sinus baroreflex-mediated sympathetic arterial pressure regulation.
Kawada T1, Shimizu S2, Turner MJ2, Fukumitsu M2, Yamamoto H3, Sugimachi M2. Life Sci. 2016 Mar 15;149:72-8. doi: 10.1016/j.lfs.2016.02.051. Epub 2016 Feb 13.
AIMS: To assess the acute effects of intravenous guanfacine, an α2A-adrenergic agonist, on sympathetic outflow from the central nervous system and on sympathetic arterial pressure (AP) response.
2.Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
Newcorn JH1, Harpin V2, Huss M3, Lyne A4, Sikirica V5, Johnson M6, Ramos-Quiroga JA7,8, van Stralen J9, Dutray B10, Sreckovic S11, Bloomfield R4, Robertson B5. J Child Psychol Psychiatry. 2016 Feb 12. doi: 10.1111/jcpp.12492. [Epub ahead of print]
BACKGROUND: Extended-release guanfacine hydrochloride (GXR), a selective α2A-adrenergic agonist, is a nonstimulant medication for attention-deficit/hyperactivity disorder (ADHD). This phase 3, double-blind, placebo-controlled, randomised-withdrawal study evaluated the long-term maintenance of GXR efficacy in children/adolescents with ADHD.
3.Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors.
Capone GT1, Brecher L2, Bay M3. J Child Neurol. 2016 Mar 2. pii: 0883073816634854. [Epub ahead of print]
The purpose of this study was to characterize children with Down syndrome and attention-deficit hyperactivity disorder (ADHD) with disruptive behaviors using the Aberrant Behavior Checklist (ABC), and to measure the treatment effects of guanfacine on maladaptive behaviors. Subjects were enrolled from a group of outpatients who visited our clinic between 2002 and 2007. Subjects (N = 23) were children with Down syndrome ages 4 to 12 years (mean 7.4 ± 4.1), who met criteria for ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. The Aberrant Behavior Checklist Irritability and Hyperactivity subscales each showed a significant decrease (P < .0001) at follow-up. The mean decline on Hyperactivity was 25% (-7.8 points), and for Irritability, 25% (-3.5 points). The mean composite score also declined by 24% (-12 points). Effect size differences on Irritability were moderate, whereas differences on Hyperactivity and composite score appeared large.